In the long struggle to understand multiple sclerosis, a two-year Swedish study of 509 newly diagnosed patients offers a partial answer and a deeper question: more aggressive early treatment can quiet the inflammatory storms of the disease, but whether that quieting protects the body over time remains unknown. B-cell-depleting therapies reduced relapses and brain lesions more effectively than oral medications, yet after two years, patients across all treatment groups were equally disabled. Science has illuminated one corridor while leaving the larger room in shadow.